Oppenheimer remains bullish on Sarepta Therapeutics (SRPT) following KOL fireside chat

Oppenheimer analyst Hartaj Singh reiterated an Outperform rating and $150.00 price target on Sarepta Therapeutics (NASDAQ: SRPT) following a KOL/management virtual fireside chat.

The analyst commented, "We hosted a virtual fireside chat with a leading Key Opinion Leader in Duchenne muscular dystrophy (DMD) and with Sarepta (SRPT) management (CEO/CFO) on 12/19. The discussions were broad-ranging: (1) regarding current treatment landscape; (2) how SRPT's antisense oligonucleotides (ASOs) have changed the treatment paradigm; and (3) how gene therapies like SRPT's SRP-9001 could further increase survival and delay progression of this deadly disease. Other topics of interest were how ASOs could still play a role in patients who do not qualify for SRP-9001 (e.g., with neutralizing antibodies), and extension of SRP-9001 to non-ambulatory DMD boys (~50–60% of total). We came away convinced that SRPT is again on the verge of initiating a paradigm shift in DMD. We stay bullish."

For an analyst ratings summary and ratings history on Sarepta Therapeutics click here. For more ratings news on Sarepta Therapeutics click here.

Shares of Sarepta Therapeutics closed at $123.00 yesterday.

You May Also Be Interested In

• New Street Research Upgrades Micron Technology (MU) to Buy
• Piper Sandler Reiterates Overweight Rating on Estee Lauder (EL), 'F4Q26 Preview'
• Intuitive Machines Inc. (LUNR) PT Lowered to $32 at Cantor Fitzgerald, Reaffirms Overweight Rating